复星医药(02196.HK)控股子公司复星医药产业与纽科签订《许可协议》

智通财经
28 Jul
【复星医药(02196.HK)控股子公司复星医药产业与纽科签订《许可协议》】智通财经APP讯,复星医药(02196.HK)公布,2025 年 7 月 28 日,公司控股子公司复星医药产业与纽科签订《许可协议》,根据约定,复星医药产业获纽科授予其在研的以 AR1001 分子作为其活性成分的药物于约定许可区域(即中国境内及港澳地区)及领域(即用于阿尔茨海默病及其他神经系统疾病的诊断、预防和治疗)的开发、注册、生产及商业化权利。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10